The "personalized cancer vaccines" (PCVs) used by the nine patients in the trial were targeted to genes specific to their ...
Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...
In an interview with THE WEEK, Professor Chuan He, lead researcher at the University of Chicago, talks about the new findings ...
In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs ...
About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...
Treatment with TNF inhibitors yielded no differences in outcomes vs. other antirheumatic therapies among U.S. veterans with ...
As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...
Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding ...
Septerna has a market cap of $750mn and $130mn in cash and ST investments. Discover SEPN's groundbreaking drug discovery ...
About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...
Lung transplant recipients are highly susceptible to infection, the researchers noted, and P. aeruginosa is a leading cause of bacterial pneumonia for them. Indeed, it was the most frequently isolated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback